MYCOPHENOLATE MOFETIL FOR INJECTION, USP 500 MG
MYCOPHENOLATE MOFETIL (MYCOPHENOLATE MOFETIL HYDROCHLORIDE) : 500 MG · DIN 02444836 · ACCORD HEALTHCARE INC
Health Canada status: MARKETED
What is MYCOPHENOLATE MOFETIL FOR INJECTION, USP?
MYCOPHENOLATE MOFETIL FOR INJECTION, USP 500 MG contains MYCOPHENOLATE MOFETIL (MYCOPHENOLATE MOFETIL HYDROCHLORIDE) : 500 MG. It is listed in the Health Canada Drug Product Database under DIN 02444836, held by ACCORD HEALTHCARE INC, supplied as POWDER FOR SOLUTION for INTRAVENOUS administration. Health Canada currently lists it as marketed, status dated 23-Apr-2019. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is MYCOPHENOLATE MOFETIL FOR INJECTION, USP used for?
Mycophenolate Mofetil for Injection, USP is indicated for: Adults: The prophylaxis of organ rejection in patients receiving allogeneic renal, cardiac or hepatic transplants. Mycophenolate mofetil should be used concomitantly with cyclosporine and corticosteroids. Mycophenolate Mofetil for Injection, USP is an alternative dosage form to mycophenolate mofetil capsules, tablets and oral suspension. Mycophenolate Mofetil for Injection, USP should be administered within 24 hours following transplantation. Mycophenolate Mofetil for Injection, USP can be administered for up to 14 days; patients should be switched to oral mycophenolate mofetil as soon as they can tolerate oral medication. Pediatrics (2-18 years of age): Mycophenolate mofetil is indicated for the prophylaxis of organ rejection in pediatric patients (2 to 18 years) receiving allogeneic renal transplants. Mycophenolate mofetil should be used concomitantly with cyclosporine and corticosteroids.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02444836 |
|---|---|
| Brand name | MYCOPHENOLATE MOFETIL FOR INJECTION, USP |
| Generic / active ingredient | MYCOPHENOLATE MOFETIL (MYCOPHENOLATE MOFETIL HYDROCHLORIDE) : 500 MG |
| Manufacturer | ACCORD HEALTHCARE INC |
| Strength | 500 MG |
| Dosage form | POWDER FOR SOLUTION |
| Route of administration | INTRAVENOUS |
| Schedule | Prescription |
| ATC code | L04AA06 MYCOPHENOLIC ACID |
| AHFS class | 90:28.00 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 23-Apr-2019 |
| Original market date | 2019-04-23 00:00:00 |
How is it stored and handled?
Keep solutions at 15 °C to 30 °C.
How is it supplied?
1 vial containing 500 mg mycophenolate mofetil in cartons of 1 vial
What can be used instead?
Other Canadian products sharing ATC code L04AA06 MYCOPHENOLIC ACID. 24 of 41 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| ACH-MYCOPHENOLATE | 250 MG | CAPSULE | ACCORD HEALTHCARE INC | MARKETED | DIN 02383780 |
| ACH-MYCOPHENOLATE | 500 MG | TABLET | ACCORD HEALTHCARE INC | MARKETED | DIN 02378574 |
| APO-MYCOPHENOLIC ACID | 180 MG | TABLET (ENTERIC-COATED) | APOTEX INC | MARKETED | DIN 02372738 |
| APO-MYCOPHENOLIC ACID | 360 MG | TABLET (ENTERIC-COATED) | APOTEX INC | MARKETED | DIN 02372746 |
| CELLCEPT | 200 MG | POWDER FOR SUSPENSION | HOFFMANN-LA ROCHE LIMITED | MARKETED | DIN 02242145 |
| CELLCEPT | 250 MG | CAPSULE | HOFFMANN-LA ROCHE LIMITED | MARKETED | DIN 02192748 |
| CELLCEPT | 500 MG | TABLET | HOFFMANN-LA ROCHE LIMITED | MARKETED | DIN 02237484 |
| CELLCEPT I.V. | 500 MG | POWDER FOR SOLUTION | HOFFMANN-LA ROCHE LIMITED | MARKETED | DIN 02240347 |
| JAMP MYCOPHENOLIC ACID | 180 MG | TABLET (ENTERIC-COATED) | JAMP PHARMA CORPORATION | MARKETED | DIN 02518538 |
| JAMP MYCOPHENOLIC ACID | 360 MG | TABLET (ENTERIC-COATED) | JAMP PHARMA CORPORATION | MARKETED | DIN 02518511 |
Who else supplies MYCOPHENOLIC ACID worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. MYCOPHENOLIC ACID appears in 252 registered pack listings across 8 markets, published on 7 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Request a quote for MYCOPHENOLATE MOFETIL FOR INJECTION, USP
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.